Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

COVID-19 'war games': the computer program that could help save your job

Wed, 11th Nov 2020 12:23

* Tech firm creates game to simulate impact of COVID layoffs

* 'Broad-front' cost-cutting strategy seen as more effective

* World of work on brink of revolution, creator says

By Sinead Cruise

LONDON, Nov 11 (Reuters) - Bank of England Chief Economist
Andy Haldane has signed up to judge the winner of a 'war game'
designed to help firms find alternatives to mass layoffs in the
face of a coronavirus-driven slowdown.

Confronted with the most unpredictable pandemic in memory,
cost-conscious firms have already axed millions of staff
worldwide, while UK redundancies hit a record high of 314,000 in
the quarter to Sept. 30, official data showed on Tuesday.

Unilever-owned tech firm uFlexReward created the
COVID-19 War Game to allow executives to explore the impact of
huge job cuts on their future earnings prospects.

"Many companies across the UK are facing financial strains
as a result of the COVID crisis," Haldane told Reuters.

"Simulation tools can help us understand how best to
alleviate these strains while preserving jobs, in a way that
helps both businesses when making difficult commercial decisions
and policymakers when making difficult economic decisions."

The game, designed during Britain's first lockdown this year
and available free to play on the uFlexReward website, calls on
players to devise a strategy to cut people costs of a fictional
firm by 20%.

Participants weigh up the pros and cons of large-scale
redundancies versus alternatives, for the long-term benefit of
the firm as well as the broader economy.

It collates staff salaries, pensions, bonuses and share
awards into one real-time cost-base, helping players see
different ways of trimming overheads more clearly.

This can include making lots of smaller cost cuts in a
so-called 'broad-front' approach, rather than one large saving
in more focused cuts like scrapping entire business units or the
staff bonus pool.

Financial firms have historically slashed highly paid
workforces on the eve of recession, only to rehire rapidly when
the economy rebounds.

Swapping this convention for a broad-front approach could
minimise the risks that employers end up understaffed and
under-skilled when the recovery kicks off, uFlexReward Chief
Executive Ken Charman said.

'CHANGE IS COMING'

Employers in multiple sectors are facing the prospect of a
broader revolution in the world of work, triggered by technology
and mass remote working.

"We are still stuck in a very Victorian view of what work is
- with fixed working days, for a single employer and in a
typically narrow role," Charman said.

"But change is coming that will allow people to be several
things at once ... if companies lose people who are highly
trained, experienced and loyal, they won't get them back," he
said.

Charman hopes the game might persuade employers to waive or
cut dividends as well as executive pay increases, and offer
job-sharing, reduced hours or part-time roles with flexibility
to work elsewhere to staff who might otherwise end up
unemployed.

Pushing through alternatives to mass layoffs will require
strong leadership and communication, particularly when thousands
of employee contracts need to be renegotiated, but retaining
staff could leave firms better placed when the recovery begins,
Charman said.

"Executives need to be willing to abandon the old
conventions; there will be resistance and they've got to be able
to convince people this is in their best interests," he said.

"Employers, big companies and big financial institutions are
part of our critical national infrastructure as much as the
National Grid. They are the engines of our growth, but they are
under threat."

Judging of the head-to-head version of the game, featuring
teams made up of executives from Unilever and NYSE-listed
technology services provider Endava, will take place on
Dec. 3.

Together with Haldane, AstraZeneca senior vice
president of reward and inclusion Rebekah Martin, Unilever head
of global reward Constantina Tribou, and author David Goodhart
are among those judging the strategies.
($1 = 0.7706 pounds)
(Reporting by Sinead Cruise; Editing by Jan Harvey)

More News
11 Apr 2024 17:13

FTSE 100 edges lower as financials drag

Lok'nStore surges to all-time high after buyout by Shurgard

*

Read more
11 Apr 2024 17:07

Banks weigh down Europe's STOXX 600 after ECB signals rate cuts

Outlook hike sends Ambu shares up

*

Read more
11 Apr 2024 15:56

London close: Stocks finish lower as ECB stands pat

(Sharecast News) - London's stock markets finished in negative territory on Thursday, as investors reacted to the European Central Bank's latest policy announcement and a producer price index release in the United States.

Read more
11 Apr 2024 11:50

LONDON MARKET MIDDAY: Europe takes hit on nerves ahead of ECB decision

(Alliance News) - European equities sunk lower at midday on Thursday, with sentiment hurt by hotter-than-expected inflation from the US crushing hopes of interest rate cuts.

Read more
11 Apr 2024 08:56

TOP NEWS: Astra plans 7% dividend hike for 2024 after no rise in 2023

(Alliance News) - AstraZeneca PLC said it intends to raise its annualised dividend for 2024, citing confidence in its business performance and cash generation.

Read more
11 Apr 2024 08:54

LONDON MARKET OPEN: European markets mixed ahead of ECB decision

(Alliance News) - European equities lacked direction early Thursday morning, ahead of an interest rate decision from the European Central Bank this afternoon.

Read more
11 Apr 2024 07:49

LONDON BRIEFING: Astra promises dividend hike; Darktrace ups guidance

(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye the latest interest rate decision from the European Central Bank, a day after a hotter-than-expected US inflation reading.

Read more
11 Apr 2024 07:20

AstraZeneca to hike 2024 dividend by 7%

(Sharecast News) - Biopharma giant AstraZeneca has announced that it will increase its annual dividend by 7%, which the board said demonstrates its confidence in the company's performance and cash generation.

Read more
8 Apr 2024 08:36

TOP NEWS: AstraZeneca hails neurological data for Ultomiris, Soliris

(Alliance News) - AstraZeneca PLC on Monday said long-term data in generalised myasthenia gravis will underscore the "vital role" of its Ultomiris and Soliris antibodies in the treatment landscape.

Read more
8 Apr 2024 07:43

LONDON BRIEFING: Astra hails neurology data; CVS flags cyberattack

(Alliance News) - London's FTSE 100 is called to open a touch higher on Monday, ahead of an interest rate decision in the eurozone and a US inflation reading later in the week.

Read more
8 Apr 2024 07:02

AstraZeneca's Enhurtu cancer gets US green light for adult patients

(Sharecast News) - AstraZeneca and Daiichi Sankyo's Enhertu cancer drug has been approved in the US for adult patients with unresectable or metastatic solid tumours who have received prior systemic treatment and have no satisfactory alternative options.

Read more
8 Apr 2024 06:53

TOP NEWS: AstraZeneca's, Daiichi's Enhertu receives US FDA approval

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Saturday announced that the US Food & Drug Administration has approved their cancer drug conjugate for patients with metastatic HER2-positive solid tumours.

Read more
5 Apr 2024 09:42

AstraZeneca makes "breakthrough" in treating small cell lung cancer

(Alliance News) - AstraZeneca PLC on Friday reported positive results relating to its Imfinzi cancer treatment in phase III trials.

Read more
5 Apr 2024 07:50

LONDON BRIEFING: Shell to book USD600 million first-quarter write-off

(Alliance News) - London's FTSE 100 is called to open lower on Friday, with hawkish remarks from Federal Reserve policymakers and fears of ratcheting Middle East tensions giving investors little to cheer about ahead of the latest US jobs data.

Read more
5 Apr 2024 07:23

AstraZeneca announces positive lung cancer treatment trial results

(Sharecast News) - AstraZeneca announced positive high-level results from a phase three trial demonstrating significant advancements in the treatment of limited-stage small cell lung cancer (LS-SCLC) on Friday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.